Curriculum Vitae

/Curriculum Vitae
Curriculum Vitae 2017-11-15T21:44:52+00:00

Dr. François SESTIER, MD, PhD, FRCPC, FACC, CIME

ADDRESS: 1851, SHERBROOKE EST, Suite 901, MONTRÉAL (QUÉBEC) H2K 4L5
PHONE: 514.738.6476
FAX: 514.738.2333
E-mail: drsestier@hotmail.com
WEBSITE: www.mae.umontreal.ca

OFFICE MANAGERS NAME: Ms France Pellerin; e-mail: francepel2@gmail.com

EDUCATION

COLLEGE DEGREE EARNED
B.Sc,  Collège St Joseph
Reims, France
1961

MEDICAL DEGREE
Faculty of Medicine
University of Nancy
Nancy, France
1961-1967

Post-Doctoral Degrees
PhD, Experimental Medicine
Mc Gill University, Montreal, Canada
1973-1977

RESIDENCY

RESIDENCY 1967-1973

St Luc Hospital, Montreal
1967-1068

Montreal Heart Institute, Montreal
1968-Dec 1969

CHU, Nancy, France Jan
1970-1973

FELLOWSHIP

Canadian Heart Foundation, Royal Victoria Hospital, Montreal 1974-1977
Bourse Monast, University of Montreal 1977-1978

BOARD CERTIFICATIONS

University of Nancy France
CES (specialty certification in Cardiology, Pneumology, Aeronautic
Medicine, and Occupational Medicine
1973

ECFMG
1973

LMCC
1974

Province of Quebec, specialty certification in Cardiology
1975

American board of Insurance medicine
1995

Microprogram of Insurance medicine and medicolegal expertise, University of Montreal.
2007

Fellow in cardiology, Royal College of Physicians and surgeons of Canada
2011

American Board of Independent Medical Examiners
2011

MEDICAL LICENSURES

France, Cardiology, Pneumology, Aeronautic Medicine, and Occupational Medicine
1973-present

Province of Quebec: Cardiology
1975-present

MEDICAL STAFF APPOINTMENTS

Cardiologist with hemodynamic privileges, Sacré-Coeur hospital, Montreal
1975-1985

Researcher, Sacré-Coeur hospital, Montreal
1975-1985

Chercheur-boursier FRSQ, Sacré-Cœur hospital, Montreal
1978-1981

Cardiologist with hemodynamic privileges, Notre-Dame hospital, Montreal
1985-2004

Director Cardiology research, Notre-Dame Hospital, Montreal
1989-2004

Cardiologist, CHUM, Hotel-Dieu, Montreal
2005-Present

ACADEMIC APPOINTMENTS

Assistant professor, Department of Physiology, University of Nancy
1970-1973

Research assistant professor, University of Montreal
1978-2004

Clinical assistant professor, University of Montreal
1987-2000

Clinical associate professor, University of Montreal
1996-2003

Director, program of Insurance medicine and medicolegal expertise
1999-present

Clinical professor, University of Montreal
2003-present

HONORS

Clin-Midy thesis prize
Creation of a chair of insurance medicine, medicolegal expertise and attitude management.
1972

PROFESSIONAL ORGANIZATIONS

1967- 2010 Member, Association des Médecins de Langue Française du Canada” (AMLFC).

1972-2000 Member, Nancy Medical Society.

1975-présent Member, American Federation for Clinical Research (AFCR).

1975-1992 Member, Société cardiaque de Montréal.

1975-présent Member, Association des Cardiologues du Québec.

1975-1978 Associate member, American College of Cardiology.

1975-1980 Associate member, American Physiological Society.

1976-1980 Member, club de recherche du Québec.

1977-présent Member, Société française de cardiologie.

1977-présent Member, Canadian cardiovascular society.

1978-1985 Member, Association des physiologistes du Nord Est.

1978-présent Fellow, American College of Cardiology.

1980-2008 Member, Canadian Physiological Society.

1985-présent Member, Canadian Life Insurance Medical Officer Association.

1988-2000 Member de la Société Québécoise d’Hypertension.

1989-2005 Member de la Société canadienne d’artéroschlérose.

1989-present Member, Circulation Council, American Heart Association.

1991-présent Member, Société des Médecins en Evaluation Medicolégale du Québec (SEEMLQ)

1991-2005 Member, Cardiovascular Scientific Advisory Board, Pfizer, Canada.

1992-2010 Member, Association des médecins du travail du Québec.

1992-1993 Member, Cardiovascular Scientific Advisory Board, Boots Pharmaceutical, Canada.

1993-présent Member, Aerospace Medical Association.

1993-présent Member, Airlines Medical Directors Association.

1993-présent Member, Société Française de Médecine Aérospatiale (SOFRAMAS).

1996-1997 President, Canadian Life Insurance Medical Office Association.

1996-2003 Président, CME committee, SEEMLQ.

1996-present Fellow of the American Academy of Insurance Medicine.

1996-present Governor, Croix-Bleue du Québec.

2002-2005 Member, Société Française de Médecine Légale et de Criminologie.

2005-present  Member, Canadian Society of Medical Evaluators

2006-present  President, New members committee, SEEMLQ

2010-2012      President, International Association of bodily damage (AIDC)

2011-2013      President, Canadian Society of Medical Evaluators

PUBLICATIONS

A) Books and published reports:

1. F Sestier: Etude de l’ajustement circulatoire en orthostatisme chez les sujets normaux et les bronchiteux chroniques.  Thèse de médecine, Nancy, 290 pages (dactylographiées), 1972.

2. F Sestier: The role of  autoregulation in myocardial perfusion heterogeneity, Ph.D. Thesis, Department of Experimental Medicine, McGill University, Montreal, 137 pages, 1977.

3. DEA Thesis: P Millet,  F Sestier, Paris, France: Haemodynamic and electrophysiological properties of low and high osmolar contrast media in the isolated rabbit heart, 1989.

4. F. Sestier : ACE inhibitors and congestive heart failure; practical detailsduring treatment in “Emerging Conception Congestive Heart Failure”. PW Armstrong Editor  – Excepta Medica Publisher, 1993.

5. F Sestier, MD Beaulieu, J Brophy, R. Dupuis, M. Jarry, J McCans, G Tremblay, L Thibault, M Nadeau : Le traitement pharmacologique de l’angine stable. Gouvernement du Québec – Conseil consultatif de pharmacologie, 1996

6. SB Penner, JR Zonir,  F Sestier: Symposium virtuel sur les inhibiteurs de l’IECA à posologie monoquotidienne. Knowledge House, 1995

7. J MO Arnold, J Davignon,  F Sestier, V Bernstein, G Fodor, B A Sussex, MR Hayden, W Warnica, GP Curnew, JC Monge, TW Wilson: HMG CoA Reductase Inhibitors- A Canadian Consensus for today. Snell Medical- communication, 1999.

8. F. Sestier, Cardiovascular Guigelines for Employability in Safety Critical Position, Railway Association of Canada, Ottawa, 2001. N.B.  Courses MMD6200, 6201, 6202, 6203, 6204, 6205, 6206, 6207, 6209, 6210, 6211, 6212, 6213, 6220, 6221, 6222, 62223,6224, 6225,6226,6227, 6230, 6231, 6232, 6233, 6234, 6235 are considered as monograhies and are deposited at the Canadian National Library.

B) Book chapters:

1. F Sestier, RR Mildenberger, GA Klassen: Temporal Heterogeneity of myocardial perfusion in Microcirculation, vol. 1, J. Grayson and W. Zingg, eds., Plenum Publ. Corp., New York, 1976, pp 288-290.

2. GA Klassen, A L’Abbate,  F Sestier, RR Mildenberger: The determinants of regional myocardial blood flow in Artherosclerosis: Metabolic, Morphologic and Clinical aspects. Advances in Experimental Medicine and Biology, vol. 82. Manning and M.D. Haust, eds., Plenum Press, New York, 1977, pp 687-692.

3. GA Klassen, DT Zborowska-Slusis, F Sestier, RR Mildenberger: The role of autoregulation in the genesis of acute myocardial ischemia.  In primary and secondary angina pectoris.  A Maseri, GA Klassen, M Lesch, eds., Grune and Stratton, Inc. New York, 1978, pp 35-46.

4. F Sestier, RR Mildenberger, DT Zborowska-Sluis, GA Klassen:  Perhexiline maleate and regional myocardial perfusion in  Perhexiline Maleate.  Proceedings of a Symposium, Strasbourg, France, September 18, 1976, Excerpta Medica, Princeton, N.J., 1978.

5. F. Sestier : Problème de la vigilance chez les pilotes de lignes … ‘’igilance et transports, aspects fondamentaux, dégradation et prévention’’. M. Vallet et S Khardi, Ed, Presses Universitaires de Lyon, Publ, 1995, p.173-177.

C) Publications in peer-reviewed journals.

1. A Lockhart, F Sestier, M Sentissi, JJ Gauthier, F Schrijen: Effects of exercise and postural changes on pulmonary haemodynamics in patients with chronic lung disease. Scand. J. Resp. Dis., 1971; 77: 77-81.

2. R Lavoie, F Sestier, G Gilbert, L Chameides, R Van Praagh, P Grondin: Double outlet right ventricle with left ventricular outflow tract obstruction due to small ventricular defect.  Amer. Heart J., 1971; 82: 290-299.

3. B Dodinot, JP Saulnier, JL Neimann,  F Sestier, B Mentre, G Faivre: Dangers de l’entraînement sentinelle au stade aigu de l’infarctus du myocarde.  Arch. mal. coeur et vaiss., 65: 1423-1432, 1972.

3. G Faivre, G Mayer,  F Sestier, A Zabel:  Les shunts gauche-droit des cardiopathies congénitales de l’adulte.  Ann. Cardiol. Angiol, 23: 177-185, 1974.

4. GA Klassen,  F Sestier, A L’Abbate, RR Mildenberger, DT Zborowska-Sluis: Effects of perhexiline maleate on coronary flow distribution in the ischaemic canine myocardium. Circulation, 54: 14-20, 1976.

5. GA Klassen,  F Sestier, A L’Abbate, RR Mildenberger, DT Zborowska-Sluis: Effects of perhexiline maleate on coronary flow distribution in the ischaemic canine myocardium. Circulation, 54: 14-20, 1976.

6. GA Klassen, A L’abbate,  F Sestier, R Mildenberger:  The determinants of regional myocardial blood flow. Adv Exp Med Biol, 82: 6870-692, 1977

7. F Sestier, RR Mildenberger, GA Klassen Redistribution in left ventricular regional flow following acute right ventricular pressure overload, Can J Physiol Pharmacol, 56: 185-190, 1978

8. F Sestier, RR Mildenberger, GA Klassen: The role of autoregulation in spatial and temporal perfusion heterogeneity of the canine myocardium.  Amer. J. Physiol., 235: H64-H71, 1978.

9. F Sestier, JY Pagny, M Sestier: Nouveaux cardiotoniques. Ann. Cardiol. Angiol., 31: 7-17, 1982.

10. A Ackaoui, R Nadeau, F Sestier, P Savard, R Primeau, R Lemieux, MC Descary: Myocardial infarction diagnosis with body surface potential mapping, electrocardiography, vectocardiography, and thallium 201 scintigraphy: a correlative study with left ventricular graphs.  Clin. and Invest. Medicine, 8: 68-77, 1985.

11. JY Pagny, F Peronnet, L Beliveau, F Sestier, R Nadeau:  Systemic and regional blood flow during graded treadmill exercise in dogs. J. Physiology, Paris, 81: 368-373, 1986.

12. RM Gagnon, M Morissette, P Laramée, G Dumont,  F Sestier, G Leclerc, F Goudreau: Efficacy of delayed percutaneous transluminal coronary angioplasty after intravenous use of streptokinase in myocardial infarction. CMAJ, 139: 405-408, 1988.

13. PJ Millet,  F Sestier, “Thrombo-embolic complication with nonionic contrast media”, Catheterization and cardiovascular diagnosis, 1989; 17(3): 192.

14. J Morais, JP Soucy, F Sestier, F Lamoureux, J Lamoureux, S Danais:  Dipyridamole testing compared to exercise stress for thallium 201 imaging in patients with left branch block. Canadian Journal of Cardiology, 6: 5-8, 1990.

15. R-M Gagnon, G Dumont, F Sestier, M Morissette, D Doyle, G-A Blaise, R Delarochellière, “The role of cardiac angioplasty in patients with associated non-cardiac medical and surgical conditions”, Can. J. Cardiol. 6(7):287-292, 1990.

16. L Rouleau, LA Moyé, J de Champlain, M Klein, D Bichet, M Packer, G Dagenais, B Sussex, JM Arnold,  F Sestier, JO Parker, MMP McEwan, V Bernstein, TE Cuddy, F Delage, C Nadeau, GA Lamas, SS Gottlieb, J McCans, MA Pfeffer, “Activation of Neurohormonal systems following acute myocardial infarction”, Amer. J. Cardiol., 1991; 68(Suppl. D): 80D-86D.

17. JL Rouleau, LA Moyé, MA Pfeffer, E Braunwald, JM Arnold, U Bernstein, TE Cuddy, GR Dagenais, EM Geltman, S Goldman, D Gordon, P Hamm, M Klein, G Lamas, J McCans, P McEwan, FJ Menapace, JO Parker,  F Sestier, B Sussex for the SAVE investigators: Comparison of Post-Myocardial Infarction Management Patterns in Canada and the United States, New England Journal of Med., 1993; 328: 779-784.

18. JL Rouleau, LA Moyé, J de Champlain, M Klein, D Bichet, M Packer, G Dagenais, B Sussex, JM Arnold, F Sestier, JO Parker, MP McEwan, V Bernstein, TE Cuddy, F Delage, C Nadeau, GA Lamas, SS Gottlieb, J McCans, MA Pfeffer:  Activation of Neurohormonal Systems in Post-Infarction Left Ventricular Dysfunction, JACC, Aug. 1993; 22: 390-398.

19. M St. John Sutton, MA Pfeffer, T Plappert, JL Rouleau, LA Moyé, GR Dagenais, GA Lamas, M Klein, B Sussex, S Goldman, FJ Menapace, JO Parker, S Lewis,  F Sestier, D Gordon, P McEwan, V Bernstein, E Braunwald for the SAVE Investigators, Brigham and Women’s Hospital, Harvard Medical School, Boston: Quantitative Two-dimensional Echocardiographic Measurements Are Major Predictors of Adverse Cardiovascular Events After Acute Myocardial Infarction. The Protective Effects of Captopril, Circulation, 1994; 89:68-75.

20. JL Rouleau, M Packer, L Moyé, J de Champlain, D Bichet, M Klein, JR Rouleau, B Sussex, JM Arnold, F Sestier, JO Parker, P McEwan, V Bernstein, TE Cuddy, G Lamas, SS Gottlieb, J McCans, C Nadeau, F Delage, CCC Wun, MA Pfeffer: Prognostic Value of Neurohumoral Activation in Patients With an Acute Myocardial Infarction: Effect of Captopril, JACC, Sept. 1994; 24:583-91.

21. G Honos, D Gossard, P Auger, A Sniderman, M Smilovitch, RM Gagnon,  F Sestier, D Savard, L Bélanger, J Lenis, C Tierney for The Canadian Study Group on Perindopril: Once Daily Perindopril Versus Slow Release Diltiazem in the Treatment of Mild to Moderate Essential Hypertension, Can J Cardiol, Nov. 1994; (Suppl. D): 10:8D-12D.

22. C Hall, JL Rouleau, L Moyé, J de Champlain, D Bichet, M Klein, B Sussex, M Packer, J Rouleau, MO Arnold, GA Lamas,  F Sestier, SS Gottlieb, CCC Wun, MA Pfeffer: NTerminal Proatrial Natriuretic Factor. An independent predictor of long-term prognosis after myocardial infarction, Circulation, 1994; 89:1934-1942.

23. MA Pfeffer, FM Sacks, LA Moyé, L Brown, JL Rouleau, LH Hautley, J Rouleau, R Grimm, F Sestier, W Wickemeyer, TG Cole, E Braunwald, for the Care Investigators : Cholesterol And Recurrent Events : a secondary prevention trial for normolipidemia patients. Amer J Cardiol 1995;76(suppl C):98C-106C.

24. FM Sacks, JL Rouleau, LA Moyé, MA Pfeffer, JW Warnica, JMO Arnold, DT Avash, LE Brown, DT Nash, LE Brown, F Sestier, J Rutherford, BR Davis, CM Hawkins, E Braunwald, for the Care Investigators : Baseline characteristics on the Cholesterol And Recurrent Events (CARE) trial of secondary prevention in patients with average serum cholesterol levels. AM J Cardiol 1995;75:621-623.

25. The Digitalis Investigation Group: The effect of Digoxin on Mortality and Morbidity in Patients with Heart Failure: N Engl J Med, 1997; 336:525-533.

26. P Tanser, M Baird, P Bogaty, V Bernstein, J Cox, B Cujec, K Finnie, A Langer, J McCans, R McKelvie, A Miller, J O Parker, B Rose,  F Sestier, W Warnica: 1997 CCS Consensual Conference on evaluation and treatment of Ischaemic heart disease: Canadian Journal of Cardiology, 1998; 14(Suppl C): 1C-24C.

27. Writing Committee; R. S. McKelvie, MD, PhD; S. Yusuf, MBBS, DPhil; D. Pericak, MMath; A. Avezum, MD; R. J. Burns, MD; J. Probstfield, MD; R. T. Tsuyuki, PharmD, MSc; M. White, MD; J. Rouleau, MD; R. Latini, MD; A. Maggioni, MD; J. Young, MD; J. Pogue, MA,  MSc:  Comparison of Candesartan, Enalapril, and Their Combination in Congestive Heart Failure  Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study: The RESOLVD Pilot Study Investigators,  Circulation. 1999;100:1056-1064

28. Milton Packer, MD; Philip A. Poole-Wilson, MD; Paul W. Armstrong, MD; John G. F. Cleland, MD; John D. Horowitz, MD; Barry M. Massie, MD; Lars Rydén, MD; Kristian Thygesen, MD; Barry F. Uretsky, MD; on behalf of the ATLAS Study Group Effects of Low and High Doses of the Angiotensin-Converting Enzyme Inhibitor, Lisinopril, on Morbidity and Mortality in Chronic Heart Failure, 100: 2312-2318, 1999

29. O Timar, F Sestier, E Levy: Metabolic Syndrome X: A review. Can. J. Cardiol 2000; 10:779-789.

30. A Naslafkih, F Sestier: Expected Versus Observed Survival in three Large Population Studies with HMG-CoA Reductase Inhibitors. Journal of Insurance Medicine 2000; 32:155-162

31. J Rouleau, MA Pfeffer, DJ Steward, D Isaac, F Sestier, EK Kerut, CB Porter, G Proulx, C Qian, AJ Block: Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000; 356:615-620.

32. The RESOLVD Investigators: Effects of Metoprolol CR in Patients with Ischaemic and Dilated Cardiomyopathy, The Randomized Evaluation of Strategies for Left Ventricular Dysfunction Pilot Study, Circulation, 2000; 101: 378-384.

33. The Heart Outcomes Preventing Evaluation Study Investigators: Effects of an angiotensinConverting-Enzyme Inhibitor, Ramipril, on Cardiovascular Events in High-Risk Patients: N. Engl J Med, 2000; 342:145-153.

34. A. Naslafkih, F. Sestier: A quicker method for calculation mortality ratios based on survival rates in clinical trials and other follow-up studies, Journal of Insurance Medicine, 2001: 33: 339-348.

35. Abdelouahed Naslafkih, MD, MSc; Francois Sestier, MD, PhD, FACC : Mortality Analysis in Patients With Atrial Fibrillation and Implantable Permanent Pacemaker After Ablation of the Atrioventricular Node, J Insur Med, 34:92-93-2002

36. Tej Sheth, MD, Tom Parker, , Alan Block, PhD, Duncan J Stewart, MD, Christian Hall, MD, Chunlin Qian, PhD, Mark A Pfeffer, MD, IMPRESS Investigators: Comparison of the effects of omapatrilat and lisinopril on circulating neurohormones and cytokines in patients with chronic heart failure, Amer J Cardiol.,90:496-500, 2002

37. Abdelouahed Naslafkih, MD, MSc; François Sestier, MD, PhD, FACC : Diabetes Mellitus Related Morbidity, Risk of Hospitalization and Disability, J Insur Med,35:102–113, 2003

38. Guillermo Torre-Amione, MD, PhD, François Sestier, MD, Branislav Radovancevic, MD, James Young, MD : Effects of a novel immune modulation therapy in patients with advanced chronic heart failure : Results of a randomized, controlled, phase II trial; J Amer Coll Cardiol, 44: 1181-1186, 2004

39. Warraich RS, Young JB, Sestier F:Clinical and prognostic relevance of lg-G3 reactivity in heart failure:a substudv of vasozen’s immune modulation therapy in patients with chronic heart failure, J Amer Coll Cardiol,43, 2004

40. Ross D, Essebag V, Sestier F et al: Assessment of the cardiac patient for fitness to fly: flying subgroup executive summary; Canadian Cardiovascular Society Consensus Conference. Can J Cardiol, 20: 1321-1323, 2004

41. Abdelouahed Naslafkih, MD, MSc; Nandini Dendukuri, PhD; James M. Brophy, MD : PhD, FACC; François Sestier, MD, PhD:  Geographical Variations in Post Myocardial Infarction: Mortality and Their Impact on Risk Selection, Amer J Insur Med, 36: 282-291, 2004

42. F Sestier:Une formation académique en médecine d’assurance et d’expertise, Pédagogie médicale, 5: 11-12, 2004

43. Guillermo Torre-Amione, MD, PhD, François Sestier, MD, Branislav Radovancevic, MD, James Young, MD :  Broad Modulation of Tissue Responses (Immune Activation) by Celacade May Favorably Influence Pathologic Processes Associated with Heart Failure Progression. Amer J Cardiol, 95:30-37,2005

44. Naslafkih A, Fix JM,  Sestier F, Khoury A: Aortic valve replacement and long-term prognosis. Amer J Insur med, 38: 126-135, 2006

45. Guillermo Torre-Amione, MD, Robert C Bourge, MD, Wilson S Colucci, MD, Barry Greenberg, MD, Craig Pratt, MD, Jean-Lucien Rouleau, MD, Francois Sestier, MD, Lemuel A Moyé, MD PhD, John A Geddes, Agnes J Nemet, MD, James B Young, MD, and for the ACCLAIM InvestigatorsA study to assess the effects of a broadspectrum immune modulatory therapy on mortality and morbidity in patients with MD, chronic heart failure: The ACCLAIM trial rationale and design, Can J Cardiol, 23:369-378, 2007

46. Naslafkih A,  Khoury A ,Sestier F: Mitral Valve Replacement and Long-term Prognosis, J Assoc Life Insur Med of Japan, 105:1-10, 2007

47. Guillermo Torre-Amione, MD, Stefan D Anker, MD, Robert C Bourge, MD, Wilson S Colucci, MD, Barry H Greenberg, MD, Per Hildebrandt, MD, Andre Keren, MD, Michael Motro, MD,  Lemuel A Moyé, MD, Jan Erik Otterstad, MD, Craig M Pratt, MD, Piotr Ponikowski, MD, Jean Lucien Rouleau, MD,  Francois Sestier, MD, Bernhard R Winkelmann, MD, James B Young, MD, for the Advanced Chronic Heart Failure CLinical Assessment of Immune Modulation Therapy Investigators, Lancet. 371: 19-25, 2008

D) Publications in journals without peer-review:

1. R Charboneau, F Sestier, J Bernier:  Pneumothorax spontanés.  A propos de 60 épisodes chez 55 patients.  Union Médicale du Canada, 97: 1191-1202, 1968.

2. J Bernier, R Charbonneau, F Sestier: A propos d’une forme localisée de granulomatose de Wegener. Union Médicale du Canada, 98: 44-54, 1969(a).

3. J Bernier, R Charbonneau, F Sestier: A propos de deux cas d’adénome bronchique de type carcinoide.  Union Médicale du Canada, 98: 412-422, 1969.

4. FSestier, J Bernier, R Charbonneau:  Bronchopneumopathie d’origine toxique par inhalation de vapeurs amoniacales.   A propos d’un cas.  Union Médicale du Canada, 98: 1903-1910, 1969.

5. J Bernier, R Charbonneau, F Sestier, G Vaillant, P Lamy: A propos d’une forme localisée de granulomatose de Wegener. Ann. Med., Nancy, 9(b): 281-290, 1970.

6. F Sestier, F Schrijen, M Sentissi, JJ Gauthier, A Lockhart: L’adaptation cardiovasculaire à l’orthostatisme: intérêt pratique de son étude chez les bronchiteux chroniques.  Ann. Méd., Nancy, 10: 1419-1425, 1971.

7. JM Polu,  F Sestier: L’hémodynamique des insuffisances respiratoires aigues.   Poumon et coeur, 28: 279-283, 1972.

8. F Sestier, F Cherrier, M Cuillère: Infarctus avec coronarographie  normale.   Ann. Méd. Nancy, 11: 779-789, 1972.

9. B Dodinot, JL Neiman, A Ferry,  F Sestier: La décennie prodigieuse ou 1,000 primoimplantations de pacemakers en 10 ans. Conc. méd., 94: 1367-1383, 1972.

10. JP Saulnier, JL Neimann, F Sestier, G Hua: Intérêt du tosylate de bretylium dans le traitement des troubles de l’excitabilité.  Ann. Méd. Nancy, 11:  1183-1191, 1972.

11. F Sestier: Influence des sympatholytiques beta sur l’hémodynamique cardiaque. Nancy Méd. post-universitaire, 1973.

12. F Sestier:  Le bilan hémodynamique des bronchopneumopathies chroniques.  Union Méd. Canada, 102: 1897-1191, 1973.

13. F Sestier, M Boulange, D Anthoine, P Lamy: Syndrome de Schwartz- Bartier et cancer bronchique anaplasique (intérêt du dosage de l’hormone antidiurétique).  Ann. Méd. Nancy,

13: 583-592, 1974. 1974.

14. JL Neimann, JP Saulnier, F Sestier:  Etude clinique du Practolol: son intérêt dans les troubles du rythme cardiaque.  Ann. Méd. Nancy, 13: 1215-1218, 1974.

15. F Sestier, H Lambert, JM Bertheau, J Leclere, MC Mangincheval, J Borrelly, D Anthoine, P Lamy: Hyperparathyroïidie paranéoplasique révélatrice d’un cancer pancréatique.  Ann. Med. Nancy, 13: 1643-1650, 1974.

16. F Sestier, F Schrijen, A Lockhart:  Effet de la dihydroergotamine sur l’hémodynamique centrale en orthostatisme.  Ann. Med. Nancy, 14: 111-120, 1975.

17. M David, F Sestier, D Hamel, Y Choquet: Un défi diagnostique: La sténose musculaire sousaortique chez la personne âgée. Union Méd. Canada, 110: 132-137, 1980.

18. E Goudreau, RM Gagnon, M Morissette, G Dumont,  F Sestier: Le rôle de l’angioplastie coronarienne simultanée à la coronarographie initiale dans le traitement de l’angine instable. Union Médicale, 117: 206, l988.

19. F Sestier, “Un patient de 29 ans consulte pour un ecg anormal”, Union Médicale du Canada, 1990; 119(5): 273.

20. F. Sestier: Cardio-Quiz – La cardioprotection est-elle possible? Quelle est son importance – Le Clinicien 1993;8:89-90.

21. P René de Cotret,  F Sestier: L’Hypercholestérolenie et la micro-albuminunie dans les maladies vasculaires artherosclérotiques: Actualité Médicale, Janvier 22, 1997: pp: 2-4

22. F Sestier, JL G Tremblay: Ace inhibitors still underused in heart failure treatment: Issues and Insights in Cardiology, July 1999.

23. A Steele,  F Sestier: Microalbuminuria, Risk Reduction and the Role of ACE Inhibition: Issues and Insights in Cardiology, November 1999.

24. R Dagenais, F Sestier, JP Hallé: Forum: Maladies cardiovasculaires: les résultats de l’étude HOPE; Actualité Médicale, Janvier 19, 2000; pp. 6-9.

25. F Sestier.  Stroke Prevention with Statine, Perspective in Cardiology.  Feb. 2001.

26. F Sestier.  Statines et prévention des accidents vasculaires cérébraux.  Le Clinicien.  Suppl. Février 2001.

E) Published abstracts.

1. F Sestier, R Schrijen, M Sentissi, F Poincelot, A Lockhart:  Respective role of pulmonary vascular elasticity (Epv) and of intrathoracic pressure (Pit) in (Ppa) postural changes in arterial pulmonary arterial pressure (Ppa) in chronic bronchitics (B).  Proc. 5 Meeting ESCI, Scheveningen, 1971, Europ. J. Investi., 1: 391-392, 1970-71.

2. F Sestier, A L’Abbate, RR Mildenberger, L Christie, GA Klassen:  Microspheres to measure spatial and temporal heterogeneity of myocardial perfusion.  Circulation, 50 (suppl 3): 204, 1974.

3. GA Klassen,  F Sestier, A L’Abbate, D Zborowska-Sluis: Ischaemia induced endocardial hypoperfusion: reversal by perhexiline.  Circulation, 50 (suppl 3): 183, 1974.

4. F Sestier, RR Mildenberger, GA Klassen: Quantitation of temporal heterogeneity of myocardial perfusion using microspheres.  Clin. Res., 22: 724A, 1974.

5. GA Klassen, DT Zborowska-Sluis, A L’Abbate, RR Mildenberger, F Sestier:  Effects of CO2 on myocardial autoregulation.  Clin. Res., 22: 723A, 1974.

6. F Sestier, RR Mildenberger, G Klassen: Temporal and spatial heterogeneity of myocardial perfusion.  Fed. Proc., 34: 414, 1975.

7. F Sestier, RR Mildenberger, GA Klassen:  Endocardial ischaemic, a consequence of right ventricular pressure overload.  Clin. Res., 23: 208A, 1975.

8. G Klassen, F Sestier, A L’Abbate, D Zborowska-Sluis:  Preservation of endocardial blood flow during ischaemia by perhexiline.  Amer. J. Cardiol., 35: 149, 1975.

9. F Sestier, R Mildenberger, G Klassen: Cyclic changes in coronary blood flow: a consequence of autoregulation.  Circulation, 52 (suppl 2): 126, 1975.

10. F Sestier, GA Klassen:  The functional myocardial unit. Clin. Res., 25: 254A, 1977.

11. F Sestier, R Mildenberger, G Klassen:  L’autorégulation:  son rôle dans l’hétérogénéité temporelle et spatiale de la perfusion myocardique.  In Proceedings of the International Union of Physiological Sciences, vol.  XIII, Paris, July 18-23, 1977.  Edited by Comité National Français des Sciences Physiologiques.

12. F Sestier, D Porquet, LC Pelletier:  Flow heterogeneity in the reperfused myocardium.  The Physiologist, 21: 107, 1978

13. F Sestier, D Porquet, LC Pelletier: Repeated regional myocardial flow studies during ischaemia and reperfusion.  Clin. Res., 26: 753, 1978.

14. F Sestier, D Porquet, LC Pelletier:  Effects of dobutamine on the distribution of cardiac output.  Clin. Res., 27: 565A, 1979.

15. JP Pagny, JB Perry, C Dargis, R Gulrajani, F Roberge, F Sestier:  Cartographie isopotentielle épicardique au cours de l’ischémie myocardique aigue expérimentale.   Union Médicale du Canada, 109: 1526, 1980.

16. F Sestier:  The role of spasm in stable angina pectoris, Cardiology specialist program, a medifact tape, Ottawa, Ontario, Canada, January 1984.

17. F.Sestier: Le Captopril dans l’insuffisance cardiaque (Captopril in the treatment of congestive heart failure).  A Squibb Pharmaceutical video tape, May 1984.

18. F Sestier: Le rôle du spasme dans l’angine stable – Cardiology family physician program – medifacts tape, Ottawa, Ontario, Canada, August 1984.

19. F Sestier, M Sestier, AM Donadieu, B Bonnemain:  Myocardial reaction to isotonic contrast media in the left coronary artery in the dog.  Radiology, 161: 327, 1986.

20. P Millet, B Bonnemain, M Sestier, F Sestier:  Arrhythmia during coronary angiography in the rabbit with ioxaglate and diatrizoate.  Clin. Res., 36: 788A, 1988.

21. P Millet, M Sestier, AM Donadieu, B Bonnemain, F Sestier: Myocardial response to isotonic contrast media during coronary angiography in the dog.  APS/Aspet 88, A6, 1988.

22. F Sestier, PJ Millet, M Sestier, G Nakhle, RM Gagnon, GR Dumont, M Morissette: Intervalles QT durant la coronarographie chez l’homme avec des produits de contraste à haute et basse osmolarité, Union Médicale du Canada, 118: 2, 1989.

23. R-M Gagnon, D Savard, F Sestier, B Coutu. Investigators:  Efficacy and safety of clentiazem as monotherapy, JACC, nov. 1990.

24. JL Rouleau, JMO Arnold, V Bernstein, TE Cuddy, GR Dagenais, EM Geltman, S Goldman, D Gordon, G Lamas, J McCans, P McEwan, FJ Menapace, JO Parker, MA Pfeffer, F Sestier, B Sussex for the SAVE Investigators: Post-Myocardial Infarction Management Patterns of Patients in the Survival and Ventricular Enlargement (SAVE) Study at Canadian and United States Centers, JACC, 1990, 15: 221 A.

25. J-L Rouleau, G-R Dagenais, M Packer, B Sussex, J Malcolm Arnold, F Sestier, JO Parker, P McEwan, V Bernstein, TE Cuddy, G Lamas, SS Gottlieb, J McCans, M Klein, D Bichet, J de Champlain, M Pfeffer:  Selective Activation of Neurohormonal Systems in Post-infarction Left Ventricular Dysfunction. JACC, 1991, 17: 21A.

26. R Taillefer, M Freeman, D Greenberg, M Picard, F Chen, F Lamoureux, D Humen, R Kloiber, J Friede, A Fung, L Rosenthal, M  Rabinovitch,  F Sestier, D Greyson, F Ens: Segmental and diagnostic comparison of 99M TC Teboroxime and 201 Thallium Plurar myocardial perfusion Imaging (Canadian Multicenter Clinical Trial). JACC, 1992; 19: 247A

27. BA Sussex, JMO Arnold, JO Parker, P McEwan, JL Rouleau, M St-John-Sutton, V Bernstein, JR Rouleau, TE Cuddy, M Klein, C Nadeau, F Delage, F Sestier, J McCans, G Lamas, SS Gottlieb, E Geltman, T Plappert, LA Moyé, E Braunwald, MA Pfeffer: Independent and interactive prognostic information of neurohormones and echocardiogram in high risk postMI patients. JACC, 1992: 205A

28. F Sestier, M Packer, J Rouleau, TE Cuddy, J Rouleau, M Klein, G Flaker, LA Moyé, E Geltman, S Goldman, V Bernstein, P McEwan, B Sussex, S Lewis, J Farham, D Hayes, T Biddle, M Pfeffer: Does ventricular tachycardia predict mortality in patients with left ventricular dysfunction after an acute myocardial infarction. JACC, 1992; 19: 199A.

29. JL Rouleau, LA Moyé, MA Pfeffer, JMO Arnold, V Bernstein, TE Cuddy, GR Dagenais, M Klein, J McCans, P McEwan, JO Parker, F Sestier, B Sussex, E Braunwald (for the SAVE Investigators): Comparison of post-myocardial infarction management patterns in Canada and in the United States. Can. J. Cardiol., 1992; 8 (Suppl.B): 98B.

30. JL Rouleau, LA Moyé, MA Pfeffer, JM Arnold, V Bernstein, TE Cuddy, GR Dagenais, EM Geltman, S Goldman, D Gordon, F Menapace, M Klein, J McCans, P McEwan, JO Parker, F Sestier, B Sussex, E Braunwald: Comparison of post-myocardial infarction management patterns in Canada and the United-States. Circulation, 1992; 86(suppl.I): 729.

31. C Hall, JL Rouleau, M Klein, B Sussex, M Packer, GA Lamas, F Sestier, SS Gottlieb, MA Pfeffer (for the SAVE study): Terminal proatrial Natriuretic factor (PRO-ANF). A uniquely powerful predictor of long term outcome after myocardial infarction. JACC, 1993; 21: 270A.

32. Packer, JL Rouleau, LA Moyé, JR Rouleau, V Bernstein, TE Cuddy, S Lewis, BA Sussex, F Sestier, S Goldman, K Jacobson, G Lamas, J McCans, DS Randall, JH Weitherman, BR Davis, E Braunwald, MA Pfeffer: Effect of Captopril on ventricular arrhythmias and sudden death in patients with left ventricular dysfunction after myocardial infarction. SAVE trial, JACC, 1993; 21: 130A.

33. JL Rouleau, M Packer, LA Moyé, J de Champlain, D Bichet, M Klein, JR Rouleau, B Sussex, M Arnold, F Sestier, JO Parker, P McEwan, V Bernstein, TE Cuddy, C Nadeau, CC Wun, M Pfeffer: Prognostic Value of Post-Infarctus Neurohormonal Activation: Effect of Captopril. Circulation, 1993; 88(Suppl.I): 394.

34. Z Li, F Sestier, R Leblanc, B Coutu, P Lacombe, L Guimond: An Interactive, User Friendly Computer Program for Heart Rate Variability Analysis, JACC, 1994 (Suppl A): 3A.

35. GW Moe, JL Rouleau, E Proulx, M Arnold, F Sestier : On behalf of the Canadian Profile Investigators: Increase mortality with flosequinan in patients with failure is accompanied by increase plasma Norepinephrine , Circulation, 1994;90(suppl I) : I-380.

36. M.Sestier, F. Sestier : New therapy in North America  with Trimebutine for an emerging pathology : IBS, Journal of Investigative Medicine, 1997;45 (1),6A.

37. C Legault, F Sestier, L Brown, L Moyé, F Sacks: Perceived health Status, Dietary Adherence and CHD outcomes in Post-MI Patients of the Cholesterol and Recurrent Events (CARE) Trial: Ccan J Cardiol, 1997, 13 (Suppl 1B):117B.

38. P Guerra, M Talajic, MA Pfeffer, JL Rouleau, J Rouleau, B A Sussex, F Sestier, M Dubuc, D Roy, B Thibault, J Leroy: Effect of Captopril on Heart Rate Variability in Patients with Left Ventricular Dysfunction: SAVE Substudy: Circulation, 1997, 96(Suppl 1):1-91.

39. L Brown, F Sestier, DT Nash, TE Cuddy, TJ Wilt, J Howard, LA Moye, L Simpson, FM Sacks: Coronary Risk Factors Predict Recurrent Coronary Events After Myocardial Infarction: Circulation, 1998; 98(Suppl 1):1-323.

40. M St John Sutton, JL Rouleau, M Talajic, F Sestier, T Plappert, E Mikes, M Arnold, L Moye, M Packer, E Braunwald, MA Pfeffer: Ventricular Arrhythmias are Closely Related to Left Ventricular Size and Mass in Patients. Post-Infarction: Experience From the Survival and Ventricular Enlargment (SAVE) Study: J Amer Coll Cardiol, 1999; 33:398A

41. F Sestier, JLG Tremblay: Les inhibiteurs de l’ECA restent sous-estimés dans le traitement de l’insuffisance cardiaque. Science et savoir en cardiologie, Juillet 1999.

42. G Torre-Amione, JB Young,  F Sestier:  Immunomodulation therapy reduces death and hospitalization in class III/IV chronic heart failure:  Results of a randomized Clinical Trial. Lancet. Vol 371 January 19, 2008

43. O Timar, F Levy, J Buithieu, M Bachand, JL Chiasson, F Sestier. Effects of irbesartan on microcirculation in hypertension patients with metabolic syndrome X – Europ. J. Clin. Invest. CIL Press.

44. RS Warraich, J Young,  F Sestier, S Mcree, MH Yacoub: the Prognostic Impact of Immunoglobulin G3 Reactivity in Heart Failure: A Substudy of  Vasogen’s Immune Modulation Therapy in Patients with Chronic Heart Failure. J Card Fail.2003; 9(5) Supplement, page S60 (Abstracts from the 7th Annual Scientific Meeting).

F) Consensus:

1. Le traitement pharmacologique de l’angine stable.  Conseil consultatif de pharmacologie, 1996 (President).

2. CCS Consensual conference on evaluation and treatment of Ischaemic Heart Disease, 1998 (member).

3. HMG CoA réductase :  Inhibitors a canadian consensus for today, 1999 (Member).

4. Cardiovascular guidelines for employability in Safety Critical Position (President), 2001

5. CCS consensus, Fitness to fly. Primary panelist.

6. CCS consensus, Congestive Heart failure. Secondary panelist

PRESENTATIONS

Over 2,000 lectures given since 1967; list available upon request

Recent national and international lectures (2011-2013):

June 1, 2013. ABIME workshop, Huntington, WV, USA.  Presentation of Chapters 4 to 11 of the 6th ed. Of the AMA guide.

May 31 2013. ABIME workshop, Huntington, WV, USA.  Presentation of 2 workshops: “Scientific Approach to Detection of Malingering and deception during an IME” and “Causation, What does the science say? “

May 29, 2013. Medico-legal workshop, CAPMR, Montreal. Presentation of a lecture: “Duties of the medical expert”.

April 24-26, 2013. Medical tourism summit 2013. Los Suenos,  Costa-Rica

March 9-11, 2013. ACC scientific meeting. San Francisco, USA.

February 1-3, 2013. IAFS, Mangalore, India. Guest lecturer: “Web-based program for Medical Experts”

January 25-27, 2013. IAMLE, Kovalam, India. Guest lecturer: “Web-based program for Insurance Medicine Medical Officers

December 7, 2012. CSME. Toronto. Guest lecturer: “Causation in Court”

November 9, 2012. JFI, Montreal, co-chair of a one day workshop on medicolegal expertise; presentation of a lecture entitled (Duties of the medical expert”

October 12, 2012. Gatineau, Quebec. Annual scientific session of the Quebec Superior Court Justices: Guest lecturer: “ How to qualify an independent expert”

October 5, 2012. Charlotte, Virginia. Guest lecturer for 2 ABIME workshops: “Causation for the Expert”; “Evidence-based clinical practice guidelines” .

September 9-12: AIDC2012, Montreal. President and co-chair of the scientific committee.

July 6, 2012. IALM 2012. Istanbul, Turkey. Guest lecturer and session Chairperson: “Insurance medicine and forensic expertise”

June 4-6, 2012. CLIMOA scientific meeting. Montreal. Guest lecturer: “Controversies in critical illness”

April 23, 2012  – Dr Sestier was an invited lecturer in San José, Costa-Rica, at the “Medical Travel Summit 2012”, on medical tourism, gathering 400 attendees. Dr. Sestier’s lecture (“Canada: an opportunity for the medical travel market”) has been added to course MMD6222-A7.

March 9-11, 2012  – Dr Sestier was an invited in Orlando, FLA, lecturer at the ABIME (American Board of Independent Medical Examiners) workshop given in Orlando, Florida,

March 9-11. Dr. Sestier gave a 90 min capsule on “Detection of exaggeration and deception during an IME” during the workshop entitled “Building a successful IME/expert Witness Practice, given by Dr Ranavaya. This lecture has been added to the lecture MMD6220-A13.

November 23, 2011 – Dr Sestier was invited for a round-table organized by the Bareau de Montréal, on the reform of the judiciary procedures, regarding the role of experts, the independence of the experts, and the coming expansion of one sole expert, chosen by both parties in Quebec Courts.

October 17-20, 2011 – Dr Sestier was an invited lecturer at AIMAVIII, the annual meeting of the Asian Insurance Medicine Association, gathering 450 attendees with lectures from the best lecturers of the large international Re-insurance companies. Dr Sestier’s lecture was entitled “Insurance Medicine, a web-based curriculum from University of Montreal; adaptation for Indian or Chinese Insurance Medical officers”. This lecture has been added to the lecture MMD6232-A1.

September 12-16, 2011  – IAFS2011. In Madeira, Portugal, from September 12 to 16, 2011, more than 1,700 delegates from 109 different countries met for 3 concomitant scientific meetings: IAFS, the 19th world meeting of the International Association of Forensic sciences, MAFS, the 5th meeting of the Mediterranean Academy of Forensic Sciences, and the WPMO, the 9th triennial meeting of the World Police Medical Officers. Every day, lectures of interest for medical experts were presented. On September 16, a whole session was devoted to the Forensic Evaluation of Permanent Impairment Rates, with lectures on the AMA guide (Dr Ranavaya), the European Guide (Dr Hélène Hugues-Bejui), and permanent impairment in the era of ICF (Dr Sestier).

September 9, 2011- The Canadian summit on ethics and regulation of medicolegal examination was held by Dr Sestier in Montreal, gathering 65 attendees, including Dr Robert, representing the federation of Canadian Provincial Colleges of Physicians. Dr Sestier lectured on the  Body of Knowledge for medical experts and on provincial differences in recommendations for medical experts. The ppt of the 9 lectures are included in course MMD6221-B2

June 8-10, 2011 – Bordeaux, France. 47 Congrès International Francophone de Médecine Légale. Dr Sestier was invited to deliver a lecture  entitled: “Medicolegal issues in the sudden death of children and teen-agers”.

May 21, 2011 – Dr Sestier was invited for a round table on long term care Insurance, during the annual scientific meeting of AMCAP, the French associations of Insurance medical Officers.

May 15-18, 2011- Toronto. Dr Sestier participated to the scientific session of CLIMOA and presented a lecture entitled: “Health Care Needs in the Next Four Decades: Should We Be Alarmed?”

January 24, 2011 – Paris. Dr Sestier was a guest lecturer at a meeting organized by University Paris VIII for the future launch in March 2012 of a formal web-based program for French medical experts, with certification, maintenance of competence and periodic recertification, at the request of the French Cour de Cassation (or Supreme Court), to harmonize competence of medical experts across the European Community

CONTINUING MEDICAL EDUCATION ACTIVITIES (2011-2013)

March 2013. ACC scientific session, San Francisco, CA

February 2013: IAFS, Bengalore, India

January 2013: IAMLE, Kovalam, India

October 2012. ABIME workshop, Charlotte, VI

September 2012: AIDC2012, Montreal

June 2012: CLIMOA, Montreal.

April 2012. Travel medicine summit. Costa-Rica

April 2012. ACC scientific session . Chicago

March 2012. ABIME workshop. Orlando, FL

October 2011, Asian Insurance Medical Association Meeting, AIMAVIII, Shengai, China

September 2011, IAFS, Madeira, Portugal

September 9, 2011- The Canadian summit on ethics and regulation of medicolegal examination, Montreal

June 8-10, 2011. 47 Congrès International Francophone de Médecine Légale, – Bordeaux, France

May 2011, CLIMOA, Toronto

April 2011, ACC scientific session, New Orleans, LO

Previous meetings available upon request.

UPDATED: May 1st, 2013

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.

This Is A Custom Widget

This Sliding Bar can be switched on or off in theme options, and can take any widget you throw at it or even fill it with your custom HTML Code. Its perfect for grabbing the attention of your viewers. Choose between 1, 2, 3 or 4 columns, set the background color, widget divider color, activate transparency, a top border or fully disable it on desktop and mobile.